Sodium–glucose co-transporter-2 (SGLT2) plays an important role in reabsorption of glucose in the kidney, and inhibition of SGLT2 has been reported as a new therapeutic strategy for diabetes [32]. This evidence concerns the gene SLC5A2 and diabetes mellitus.